Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barbara Konkle

Hematology Seattle, WA Medical Doctor

NPI 1972545796 CMS profile 316498

921 Terry Ave, Puget Sound Blood Center, Seattle, WA 98104

Open in the dashboard

General payments

$249,822

159 records reported · program years 2019–2025

Research payments

$32,565

Paid to them · 61 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,300,905 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Barbara Konkle of Seattle, WA is reported in the CMS Open Payments database as having received $249,822 across 159 general payments and $32,565 in research payments paid to them. Separately, studies naming them as principal investigator received $1,300,905 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,914 12
2025 Research $1,690 3
2024 General $63,797 42
2024 Research $5,440 10
2023 General $64,445 48
2023 Research $4,520 6
2022 General $30,418 19
2022 Research $6,720 9
2021 General $33,191 7
2021 Research $4,552 10
2020 General $8,633 5
2020 Research $4,547 12
2019 General $16,425 26
2019 Research $5,096 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Konkle
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Barbara Konkle were reported at $32,914. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Barbara Konkle Hematology median Middle half National median
2019 $16,425 $1,012 $122–$9,834 $163
2020 $8,633 $1,475 $115–$9,198 $114
2021 $33,191 $1,470 $125–$7,444 $132
2022 $30,418 $1,371 $139–$8,471 $149
2023 $64,445 $1,295 $147–$11,010 $160
2024 $63,797 $1,286 $146–$9,230 $164
2025 $32,914 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $73,043 40 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $49,277 8 payments
  3. BioMarin Pharmaceutical Inc. $40,688 38 payments
  4. Spark Therapeutics, Inc. $17,728 6 payments
  5. Bioverativ Therapeutics Inc. $14,387 11 payments
  6. Regeneron Pharmaceuticals, Inc. $10,286 8 payments
  7. Pfizer Limited $10,149 4 payments
  8. Sanofi US Services Inc. $9,536 2 payments
  9. Genzyme Corporation $8,408 15 payments
  10. Octapharma USA, Inc. $8,255 16 payments
  11. Other $8,065 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $102,342 46 payments
  2. Travel and Lodging $75,024 55 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,726 27 payments
  4. Honoraria $21,875 4 payments
  5. Food and Beverage $1,794 25 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,049 1 payment
  7. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. FEIBA $46,790 6 payments
  2. XYNTHA $10,149 4 payments
  3. BENEFIX $10,149 4 payments
  4. ELITEK $9,997 9 payments
  5. NUWIQ $8,243 15 payments
  6. Roctavian $3,900 7 payments
  7. OXBRYTA $3,543 1 payment
  8. HYMPAVZI $3,125 2 payments
  9. VONVENDI $2,488 2 payments
  10. BEQVEZ $2,033 2 payments
  11. Other $7,493 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $14,040 21 payments
  2. Genzyme Corporation $10,000 20 payments
  3. Bioverativ Therapeutics Inc. $7,031 17 payments
  4. F. Hoffmann-La Roche AG $1,494 3 payments

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record